Millennium Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-136,116
| Closed | -$1.31M | – | 6616 |
|
|
2024
Q4 | $1.31M | Sell |
136,116
-2,057,639
| -94% | -$10.7M | ﹤0.01% | 3983 |
|
|
2024
Q3 | $6.27M | Buy |
2,193,755
+1,550,785
| +241% | +$4.8M | ﹤0.01% | 2641 |
|
|
2024
Q2 | $1.88M | Sell |
642,970
-10,443
| -2% | -$28.6K | ﹤0.01% | 3586 |
|
|
2024
Q1 | $2.08M | Buy |
653,413
+60,835
| +10% | +$203K | ﹤0.01% | 3697 |
|
|
2023
Q4 | $1.99M | Sell |
592,578
-1,961,594
| -77% | -$5.05M | ﹤0.01% | 3613 |
|
|
2023
Q3 | $6.08M | Buy |
2,554,172
+1,409,821
| +123% | +$2.95M | ﹤0.01% | 2523 |
|
|
2023
Q2 | $2.01M | Buy |
1,144,351
+168,739
| +17% | +$431K | ﹤0.01% | 3478 |
|
|
2023
Q1 | $3M | Sell |
975,612
-671,285
| -41% | -$4.02M | ﹤0.01% | 3049 |
|
|
2022
Q4 | $8.73M | Buy |
1,646,897
+1,495,099
| +985% | +$6.83M | ﹤0.01% | 2283 |
|
|
2022
Q3 | $536K | Sell |
151,798
-860,717
| -85% | -$2.85M | ﹤0.01% | 4914 |
|
|
2022
Q2 | $2.61M | Buy |
1,012,515
+177,929
| +21% | +$495K | ﹤0.01% | 3429 |
|
|
2022
Q1 | $3.74M | Sell |
834,586
-61,928
| -7% | -$279K | ﹤0.01% | 3252 |
|
|
2021
Q4 | $6.1M | Sell |
896,514
-13,342
| -1% | -$90.9K | ﹤0.01% | 2692 |
|
|
2021
Q3 | $6.63M | Sell |
909,856
-136,267
| -13% | -$1.17M | ﹤0.01% | 2551 |
|
|
2021
Q2 | $10.5M | Sell |
1,046,123
-718,382
| -41% | -$6.43M | 0.01% | 1838 |
|
|
2021
Q1 | $16.9M | Buy |
1,764,505
+289,976
| +20% | +$2.84M | 0.01% | 1239 |
|
|
2020
Q4 | $16.2M | Buy |
1,474,529
+1,008,070
| +216% | +$10.6M | 0.01% | 1246 |
|
|
2020
Q3 | $4.14M | Buy |
+466,459
| New | +$5.31M | 0.01% | 2009 |
|
Other funds holding PSTX
Millennium Management's PSTX Position: Q1 2025 in Review
Millennium Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 136,116 shares — an estimated $1.31M sold.
Millennium Management first reported a position in PSTX in Q3 2020 and held it in 18 quarters. The position peaked at $16.9M in Q1 2021. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- Millennium Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Millennium Management sold 136,116 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1.31M.
- Millennium Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 18 quarters.
- Millennium Management's Poseida Therapeutics, Inc. Common Stock position peaked at $16.9M in Q1 2021.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Millennium Management's 13F filing for Q1 2025, filed 15 May 2025.